From: Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio
Disease
Patients
Tumor absorbed dose (Gy)
Tumor response
Colorectal cancer
15
136.7 (43.4–494.8)
47%
Hepatocellular carcinoma
5
135.2 (57.0–310.0)
80%
Neuroendocrine tumors
10
123.6 (40.1–262.7)
100%
Other
89.6 (56.2–208.4)
60%